{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-343519","form_type":"8-K","ticker":"MREO","cik":"0001719714","company_name":"Mereo BioPharma Group plc","filed_at":"2026-08-11T12:26:13+00:00","discovered_at":"2026-08-11T12:30:00.326910+00:00","generated_at":"2026-08-11T12:30:16.790903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Mereo Q2 net loss narrows to $7M; Sentynl alvelestat option deal worth up to $475M","bullets":["Q2 2026 net loss $7.0M vs $14.6M in Q2 2025; R&D down $3.6M to $1.8M.","Cash $30.1M at June 30, 2026; runway into late-2027, excluding $40M option exercise payment.","Sentynl (Zydus sub) option for alvelestat U.S. rights: $40M upfront/R&D on exercise, up to $435M milestones, double-digit royalties.","Setrusumab Phase 3 missed primary fracture endpoint but hit key secondary BMD and PRO endpoints; FDA/MHRA discussions ongoing.","Phase 3 alvelestat trial planned for early 2027 if option exercised."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-343519","json":"https://secwatch.observer/filing/0001193125-26-343519.json","markdown":"https://secwatch.observer/filing/0001193125-26-343519.md","text":"https://secwatch.observer/filing/0001193125-26-343519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/0001193125-26-343519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526343519/mreo-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:30:16.790903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}